Qyuns Therapeutics Co Ltd

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, focuses on biologic therapies for autoimmune and allergic diseases in the People's Republic of China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor for the treatment of ankylosing spondylitis (AS) and lupus nephritis (LN); and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra to treat atopic dermatitis (AD), prurigo nodularis (PN), chronic rhinosinusitis with nasal polyps (CRSwNP), chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). The company also develops QX001S, an IL-12/IL-23p40 inhibitor for the treatment of psoriasis (Ps) and ulcerative colitis (UC)/Crohn's disease (CD); QX004N an IL-23p19 inhibitor to treat Ps and CD; QX006N, an IFNAR1-targeting mAb for the treatment of systemic lupus erythematosus (SLE); and QX008N, a humanized IgG1 mAb targeting thymic stromal lymphopoietin designed to treat moderate-to-severe asthma and COPD. In addition, it develops QX007N targeting IL-33 for the treatment of COPD and asthma; QX013N, a humanized IgG1 mAb targeting c-kit to treat CSU; and QX010N, an IL-31R inhibitor for the treatment of pruritus. The company engages in the research, development, and production of pharmaceutical products; and provision of technical consultation services. Qyuns Therapeutics Co., Ltd. was founded in 2015 and is headquartered in Taizhou, China.